

Development of Human, Rat and Dog Liver-Chips to Facilitate Safety Assessment of Candidate Drugs

Lorna Ewart, Ph.D. Executive Vice President, Science January 20, 2021


Imagine the Scenario ...



- You are a project toxicologist on a biopharmaceutical company's highest priority project that is about to go into Phase I clinical trials
- The candidate drug shows a liver toxicity signal in the large animal species but not the small animal species
- The project team want to know the relevance for human and whether they have a margin to enable progression




What are Your Options?



- Perform further animal studies to learn about the mechanism of toxicity and thus determine whether this mechanism may translate to human
- Consult the literature for previous precedent of this mechanism in animals and humans
- Explore whether toxicity is on or off-target



But What if There was an Alternative?



- Organ-Chips can bridge between conventional in vitro and in vivo models by faithfully recreating physiology, function and disease phenotypes
- Cell viability and functionality can be maintained for extended durations
- Microfluidics enables recapitulation of clinical exposure profiles
- Agnostic to cell type (e.g., cell line, primary cell, induced pluripotent stem cell, fragmented organoids)
- Agnostic to cell source (e.g., animal or human)





RESEARCH ARTICLE | DRUG TESTING

Reproducing human and cross-species drug toxicities using a Liver-Chip


© Kyung-Jin Jang^{1,*}, © Monicah A. Otieno^{2,*,†}, © Janey Ronxhi¹, © Heng-Keang Lim³, © Lorna Ewart⁴, © Konstantia R. ... + See all authors and affiliations

Science Translational Medicine 06 Nov 2019: Vol. 11, Issue 517, eaax5516 DOI: 10.1126/scitranslmed.aax5516




Liver-Chip Configuration

- 1. Top Channel
- 2. Extracellular Matrix
- 3. Hepatocytes
- 4. Porous Membrane
- 5. Stellate Cells
- 6. Kupffer Cells
- 7. Endothelial Cells
- 8. Bottom Channel








Morphology in Liver-Chip vs. Plate Sandwich Culture


Day 14 in Culture



Hepatocytes from three different species maintained their stereotypical *in vivo*-like morphologies and formed improved bile canalicular networks compared to plate sandwich culture over 2 weeks in culture



Liver-Chip: Albumin and Urea Secretion





Human, Rat and Dog Liver-Chips have higher levels of albumin and urea secretion compared to Sandwich Plate Culture over a 2-week period




Liver-Chip: Major P450 Enzyme Activities

Human, Rat and Dog Liver-Chips maintain higher levels of Cytochrome P450 activity compared to Sandwich Plate Culture over 2 weeks










Species Differences in Drug Transporters Drive Liver Toxicity


Effect of Bosentan on Albumin Secretion




Demonstrated species differences in the hepatotoxicity at *in vivo* relevant doses of Bosentan

Albumin data shows concentration response effects for dog and human, but not for rat, which correlates with *in vivo data:* human > dog > rat


Inhibition of BSEP Transporter








Modeling Rat In Vivo using the Rat Liver-Chip









Rat Liver-Chip data correlated with rat *in vivo* data and human Liver-Chip indicates low risk for toxicity

Modeling Dog in vivo using the Dog Liver-Chip


Dog In Vivo

Hepatocellular necrosis, portal fibrosis, biliary hyperplasia associated and significant elevations of ALT and AST after daily dosing at 15 and 65 mg/kg in dogs (Cmax plasma 12.7 and 19.4 μM, respectively)





Dog Liver-Chip




JNJ-G caused similar changes in Dog Liver-Chip data compared to *in vivo* data. For this compound albumin was a sensitive marker of hepatocyte dysfunction in the Liver-Chip




Use of Liver-Chip to Query Human Relevance of Dog Toxicity

Dog Liver-Chips were more sensitive to JNJ-G than human Liver-Chips but the response in the human Liver-Chip indicates that JNJ-G could induce liver toxicity in human subjects





Predicting Human Safety Risk with Liver-Chip



Fialuridine (FIAU) caused toxicity in clinical trial and patient death from liver failure (microvascular steatosis)

Toxicity not predicted in pre-clinical animal safety studies




Liver-Chip demonstrated species differences in progression to steatosis

Human Liver-Chip data correlated with clinical findings

Predicting Human Safety Risk with Liver-Chip

Liver-Chip predicted human liver toxicity of Fialuridine that was observed in clinical trial, and provides mechanistic data





Summary

- The Emulate Liver-Chip has been characterized using primary cells from human, rat or dog
- Chips display morphological markers and functional activities characteristic of hepatocytes
- Rat Liver-Chips were able to recreate rat in vivo outcome and dog Liver-Chips were able to recreate dog in vivo outcome
- Human Liver-Chips and rat Liver-Chips correctly identified the steatosis induced by fialuridine

- Taken together, these results suggest that Liver-Chips play a valuable role in risk assessment of new candidate drugs and can delineate speciesspecific toxicities and may contribute to a reduction in animal usage associated with strengthening a weight of evidence argument
- Looking forward, continued investment in access to fresh and cryopreserved animal cells will enable additional animal chips to be developed



